Elevated MCL1 is a hallmark of FBW7‐deficient CRC and drives resistance to regorafenib [20, 27], sorafenib [27], microtubule‐targeting agents [25], and Hsp90 inhibitors [26]. The gene discussed is MCL1; the disease is colorectal carcinoma.